Nephrogenic systemic fibrosis;Fibrose systémique néphrogénique

Revue de Medecine Interne

Volumn 32, Issue 6, 2011, Pages 358-362

  Frances C ^a   Senet, P ^a   Lipsker, D ^b  

^a HÔPITAL TENON   (France)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Gadolinium; Renal failure; Systemic fibrosis

Indexed keywords

CD34 ANTIGEN; GADOLINIUM;

BODY DISTRIBUTION; CARDIOMYOPATHY; CAUSAL ATTRIBUTION; CELL INFILTRATION; CONTRAST ENHANCEMENT; DIAPHRAGM PARALYSIS; HUMAN; JOINT CONTRACTURE; KIDNEY FAILURE; LUNG FIBROSIS; MORTALITY; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; SCLEROSIS; SHORT SURVEY; SKIN FIBROSIS; SKINFOLD THICKNESS; SYSTEMIC DISEASE;

HUMANS; NEPHROGENIC FIBROSING DERMOPATHY;

EID: 79956156328     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2009.07.023     Document Type: Short Survey

References (36)

1. Cowper S.E., Su L.D., Bhawan J., Robin H.S., LeBoit P.E. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001, 23:383-393.
2. Marckmann P. Nephrogenic systemic fibrosis: epidemiology update. Curr Opin Nephrol Hypertens 2008, 17:315-319.
3. Swartz R.D., Crofford L.J., Phan S.H., Ike R.W., Su L.D. Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med 2003, 114:563-572.
4. Mendoza F.A., Artlett C.M., Sandorfi N., Latinis K., Piera-Velazquez S., Jimenez S.A. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 2006, 35:238-249.
5. Nainani H., Panesar M. Nephrogenic systemic fibrosis. Am J Nephrol 2009, 291:1-9.
6. Janus N., Launay-Vacher V., Karie S., Clement O., Ledneva E., Frances C., et al. Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the FINEST study. Eur J Radiol 2010, 73:357-359.
7. Marckmann P., Skov L., Rossen K., Thomsen H.S. Clinical manifestation of gadodiamide-related nephrogenic systemic fibrosis. Clin Nephrol 2008, 69:161-168.
8. Sadowski E.A., Benett L.K., Chan M.R., Wentland A.L., Garett A.L., Garett R.W., et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007, 243:148-157.
9. Ortonne N., Lipsker D., Chantrel F., Boehm N., Grosshans E., Cribier B. Presence of CD45RO+ CD34+ cells with collagen synthesis activity in nephrogenic fibrosing dermopathy: a new pathogenic hypothesis. Br J Dermatol 2004, 150:1050-1052.
10. LeBoit P.E. What nephrogenic fibrosing dermopathy might be. Arch Dermatol 2003, 139:928-930.
11. Marckmann P., Skov L., Rossen K., Dupont A., Damholt M.B., Heaf J.G., et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006, 17:2359-2362.
12. Jiménez S.A., Artlett C.M., Sandorfi N., Derk C., Latinis K., Sawaya H., et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy). Study of inflammatory cells and TGF-ß1 expression in affected skin. Arthritis Rheum 2004, 50:2660-2666.
13. Todd D.J., Kagan A., Chibnik L.B., Kay J. Cutaneous changes of nephrogenic systemic fibrosis. Arthritis Rheum 2007, 56:3433-3441.
14. Mathur K., Morris S., Deighan C., Green R., Douglas K.W. Extracorporeal photopheresis improves nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: three case reports and review of literature. J Clin Apher 2008, 23:144-150.
15. Kay J., High W.A. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum 2008, 58:2543-2548.
16. Knopp E.A., Cowper S.E. Nephrogenic systemic fibrosis: early recognition and treatment. Semin Dial 2008, 21:123-128.
17. Deng A.C., Bilu D.M., Sina B., Gaspari A. Localized nephrogenic fibrosing dermopathy: aberrant dermal repairing?. J Am Acad Dermatol 2008, 58:336-339.
18. Swaminathan S., Ahmed I., McCarthy J.T., Albright R.C., Pittelkow M.R., Caplice N.M., et al. Nephrogenic fibrosing dermopathy and high dose erythropoietin therapy. Ann Intern Med 2006, 145:234-235.
19. Marckmann P., Skov L., Rossen K., Heaf J.G., Thomsen H.S. Case control study of gadiodamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 2007, 22:3174-3178.
20. Cowper S.E. Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol 2003, 15:785-790.
21. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant 2006, 21:1104-1108.
22. Broome D.R., Girguis M.S., Baron P.W., Cottrell A.C., Kjellin I., Kirk G.A. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. Am J Roentgenol 2007, 188:586-592.
23. Deo A., Fogel M., Cowper S.E. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2007, 2:264-267.
24. Lauenstein T.C., Salman K., Morreira R., Tata S., Tudorascu D., Baramidze G., et al. Nephrogenic systemic fibrosis: center case review. J Magn Reson Imaging 2007, 26:1198-1203.
25. Cowper S.E. Nephrogenic systemic fibrosis: a review and exploration of the role of gadolinium. Adv Dermatol 2007, 23:131-154.
26. Boyd A.S., Zic J.A., Abraham J.L. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007, 56:27-30.
27. High W.A., Ayers R.A., Chandler J., Zito G., Cowper S.E. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007, 56:21-26.
28. Swaminathan S., High W.A., Ranville J., Horn T.D., Hiatt K., Thomas M., et al. Cardiac and vascular metal deposition with high mortality in nephrogenic systemic fibrosis. Kidney Int 2008, 73:1413-1418.
29. Saussereau E., Lacroix C., Cattaneo A., mahieu L., Goulle J.P. Hair and fingernail gadolinium ICP-MS contents in an overdose case associated with nephrogenic systemic fibrosis. Forensic Sci Int 2008, 176:54-57.
30. Abraham J.L., Thakral C., Skov L., Rossen K., Marckmann P. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long term persistence in nephrogenic systemic fibrosis. Br J Dermatol 2008, 158:273-280.
31. Edward M., Quinn J.A., Mukherjee S., Jensen M.B.V., Jardine A.G., Mark P.B., et al. Gadodiamide contrast agent activates fibroblasts: a possible cause of nephrogenic systemic fibrosis. J Pathol 2008, 214:584-593.
32. Varani J., Dasilva M., Warner R.L., O'Brien Deming M., Barron A.G., Johnson K.J., et al. Effects of gadolinium-based magnetic resonance imaging contrast agents on human skin in organ culture and human skin fibroblasts. Invest Radiol 2009, 7:74-81.
33. Sieber M.A., Pietsch H., Walter J., Haider W., Frenzel T., Weinmann H.J. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol 2008, 43:65-75.
34. Thomsen H.S., Morcos S.K. Nephrogenic systemic fibrosis and non ionic linear chelates. Am J Roentgenol 2007, 188:580.
35. Idée J.M., Port M., Medina C., Lancelot E., Fayoux E., Ballet S., et al. Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review. Toxicology 2008, 248:77-88.
36. Marckmann P., Nielsen A.H., Sloth J.J. Possibly enhanced Gd excretion in dialysate, but no major clinical benefit of 3-5 months of treatment with sodium thiosulfate in late stages of nephrogenic systemic fibrosis. Nephrol Dial Transplant 2008, 23:3280-3282.